skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures

Abstract

Purpose: To describe our experience with ultrasound (US)-guided percutaneous liver biopsies using the INRAD 18G Express core needle biopsy system.Methods: One hundred and fifty-four consecutive percutaneous core liver biopsy procedures were performed in 153 men in a single institution over 37 months. The medical charts, pathology reports, and radiology files were retrospectively reviewed. The number of needle passes, type of guidance, change in hematocrit level, and adequacy of specimens for histologic analysis were evaluated.Results: All biopsies were performed for histologic staging of chronic liver diseases. The majority of patients had hepatitis C (134/153, 90.2%). All patients were discharged to home after 4 hr of postprocedural observation. In 145 of 154 (94%) biopsies, a single needle pass was sufficient for diagnosis. US guidance was utilized in all but one of the procedures (153/154, 99.4%). The mean hematocrit decrease was 1.2% (44.1-42.9%). Pain requiring narcotic analgesia, the most frequent complication, occurred in 28 of 154 procedures (18.2%). No major complications occurred. The specimens were diagnostic in 152 of 154 procedures (98.7%).Conclusions: Single-pass percutaneous US-guided liver biopsy with the INRAD 18G Express core needle biopsy system is safe and provides definitive pathologic diagnosis of chronic liver disease. It can be performed on anmore » outpatient basis. Routine post-biopsy monitoring of hematocrit level in stable, asymptomatic patients is probably not warranted.« less

Authors:
; ; ; ; ; ;  [1]
  1. UCSD Medical Center, Department of Radiology (United States)
Publication Date:
OSTI Identifier:
21091350
Resource Type:
Journal Article
Journal Name:
Cardiovascular and Interventional Radiology
Additional Journal Information:
Journal Volume: 28; Journal Issue: 5; Other Information: DOI: 10.1007/s00270-004-0017-5; Copyright (c) 2005 Springer Science+Business Media, Inc.; www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0174-1551
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; BIOPSY; DIAGNOSIS; HEPATITIS; LIVER; NARCOTICS; PATHOLOGY; PATIENTS

Citation Formats

Rivera-Sanfeliz, Gerant, E-mail: gerantrivera@ucsd.edu, Kinney, Thomas B., Rose, Steven C., Agha, Ayad K.M., Valji, Karim, Miller, Franklin J., and Roberts, Anne C. Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures. United States: N. p., 2005. Web. doi:10.1007/S00270-004-0017-5.
Rivera-Sanfeliz, Gerant, E-mail: gerantrivera@ucsd.edu, Kinney, Thomas B., Rose, Steven C., Agha, Ayad K.M., Valji, Karim, Miller, Franklin J., & Roberts, Anne C. Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures. United States. doi:10.1007/S00270-004-0017-5.
Rivera-Sanfeliz, Gerant, E-mail: gerantrivera@ucsd.edu, Kinney, Thomas B., Rose, Steven C., Agha, Ayad K.M., Valji, Karim, Miller, Franklin J., and Roberts, Anne C. Wed . "Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures". United States. doi:10.1007/S00270-004-0017-5.
@article{osti_21091350,
title = {Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures},
author = {Rivera-Sanfeliz, Gerant, E-mail: gerantrivera@ucsd.edu and Kinney, Thomas B. and Rose, Steven C. and Agha, Ayad K.M. and Valji, Karim and Miller, Franklin J. and Roberts, Anne C.},
abstractNote = {Purpose: To describe our experience with ultrasound (US)-guided percutaneous liver biopsies using the INRAD 18G Express core needle biopsy system.Methods: One hundred and fifty-four consecutive percutaneous core liver biopsy procedures were performed in 153 men in a single institution over 37 months. The medical charts, pathology reports, and radiology files were retrospectively reviewed. The number of needle passes, type of guidance, change in hematocrit level, and adequacy of specimens for histologic analysis were evaluated.Results: All biopsies were performed for histologic staging of chronic liver diseases. The majority of patients had hepatitis C (134/153, 90.2%). All patients were discharged to home after 4 hr of postprocedural observation. In 145 of 154 (94%) biopsies, a single needle pass was sufficient for diagnosis. US guidance was utilized in all but one of the procedures (153/154, 99.4%). The mean hematocrit decrease was 1.2% (44.1-42.9%). Pain requiring narcotic analgesia, the most frequent complication, occurred in 28 of 154 procedures (18.2%). No major complications occurred. The specimens were diagnostic in 152 of 154 procedures (98.7%).Conclusions: Single-pass percutaneous US-guided liver biopsy with the INRAD 18G Express core needle biopsy system is safe and provides definitive pathologic diagnosis of chronic liver disease. It can be performed on an outpatient basis. Routine post-biopsy monitoring of hematocrit level in stable, asymptomatic patients is probably not warranted.},
doi = {10.1007/S00270-004-0017-5},
journal = {Cardiovascular and Interventional Radiology},
issn = {0174-1551},
number = 5,
volume = 28,
place = {United States},
year = {2005},
month = {6}
}